Search
Now showing items 4261-4270 of 4393
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
(SPRINGER, 2024-03-02)
BACKGROUND: Selective biomarkers may improve outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitor therapy. We investigated three ...
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
(ELSEVIER, 2024-03-01)
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as ...
Workshop report: the clinical application of data from multiplex assays of variant effect (MAVEs), 12 July 2023.
(SPRINGERNATURE, 2024-05-01)
Clinical classification of genomic variants identified on sequencing is often challenging, with many variants classified as Variants of Uncertain Significance (VUS) on account of insufficient evidence. Advances in sequencing ...
Structural basis for the modulation of MRP2 activity by phosphorylation and drugs.
(NATURE PORTFOLIO, 2024-03-04)
Multidrug resistance-associated protein 2 (MRP2/ABCC2) is a polyspecific efflux transporter of organic anions expressed in hepatocyte canalicular membranes. MRP2 dysfunction, in Dubin-Johnson syndrome or by off-target ...
Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.
(Elsevier BV, 2024-03-01)
For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies have changed significantly due to the introduction of targeted therapies and immunotherapy. In the last few years, we have seen an ...
Cancer Evolution: A Multifaceted Affair.
(AMER ASSOC CANCER RESEARCH, 2024-01-12)
UNLABELLED: Cancer cells adapt and survive through the acquisition and selection of molecular modifications. This process defines cancer evolution. Building on a theoretical framework based on heritable genetic changes has ...
Monoclonal Antibodies for Targeted Fluorescence-Guided Surgery: A Review of Applicability across Multiple Solid Tumors.
(MDPI, 2024-03-04)
This study aims to review the status of the clinical use of monoclonal antibodies (mAbs) that have completed or are in ongoing clinical trials for targeted fluorescence-guided surgery (T-FGS) for the intraoperative ...
Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays.
(NATURE PORTFOLIO, 2022-11-03)
By suppressing gene transcription through the recruitment of corepressor proteins, B-cell lymphoma 6 (BCL6) protein controls a transcriptional network required for the formation and maintenance of B-cell germinal centres. ...
Pharmacotherapy for liposarcoma: current and emerging synthetic treatments.
(TAYLOR & FRANCIS LTD, 2021-04-21)
Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ...
An Incidental Renal Oncocytoma: 18F-Choline PET/MRI
(MDPI AG, 2016-04-06)
<jats:p>PET/MRI is a new hybrid imaging modality and has the potential to become a powerful imaging tool. It is currently one of the most active areas of research in diagnostic imaging. The characterisation of an incidental ...